echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Additional use of hydroxychloroquine increases live birth rates in women with persistently positive antiphospholipid antibodies

    Additional use of hydroxychloroquine increases live birth rates in women with persistently positive antiphospholipid antibodies

    • Last Update: 2022-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disorder defined as recurrent thrombotic and/or obstetric disease with persistent antiphospholipid antibody (aPL) positivity, including lupus anticoagulants, anti-beta-2 Glycoprotein I and/or anticardiolipin antibodies


    In previous studies, treatment with low-dose aspirin and therapeutic-dose heparin in patients with APS was associated with higher live birth rates (mean 79% of pregnancies)


    No teratogenic effects have been reported with the use of hydroxychloroquine during pregnancy


    Recent in vitro and in vivo studies suggest that inflammatory processes may be responsible for obstetric complications in women with aPL


    METHODS: From inception to 31 December 2019, a systematic search of the PubMed, EMBASE and Cochrane Central Register of Controlled Trials databases was performed


    RESULTS: Five retrospective studies involving 477 pregnancies were selected


    In conclusion, unlike other systematic reviews of pregnancy morbidity associated with hydroxychloroquine and antiphospholipid antibodies, data from this study suggest that receiving HCQ as add-on therapy improves live birth rates in pregnant women with persistent antiphospholipid antibodies


    Reference: Tian Y, Xu J, Chen D, Yang C, Peng B.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.